SCHEMBL5951864

SCHEMBL5951864

CC(Cl)C(=O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.61
CES2 O00748 2/20 0.58
CES1 P23141 2/20 0.58
SRD5A2 P31213 1/20 0.48
NR4A1 P22736 1/20 0.47
NR4A2 P43354 1/20 0.47
NR4A3 Q92570 1/20 0.47
PTPN1 P18031 2/20 0.47
SLC6A4 P31645 1/20 0.47
TRPV1 Q8NER1 2/20 0.45
MEN1 O00255 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
LSS P48449 1/20 0.42
CYP1A1 P04798 1/20 0.41
CYP1B1 Q16678 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
EPHX2 P34913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8534398 0.84 GSK3B (0.66) GSK3BCES2CES1SRD5A2NR4A1
SCHEMBL11850488 0.82 HDAC1 (0.52) SRD5A2MEN1TSHRKMT2ANPC1
SCHEMBL2075210 0.82 GSK3B (0.63) GSK3BCES2CES1SRD5A2NR4A1
SCHEMBL28853761 0.82 GSK3B (0.63) GSK3BCES2CES1SRD5A2NR4A1
SCHEMBL8553654 0.82 CES2 (0.65) GSK3BCES2CES1SRD5A2NR4A1
SCHEMBL21565745 0.81 GSK3B (0.61) GSK3BCES2CES1SRD5A2NR4A1
SCHEMBL19520441 0.81 GSK3B (0.61) GSK3BCES2CES1SRD5A2NR4A1
SCHEMBL19866845 0.81 GSK3B (0.61) GSK3BCES2CES1SRD5A2NR4A1
SCHEMBL786834 0.81 GSK3B (0.72) GSK3BCES2CES1SRD5A2NR4A1
SCHEMBL14392841 0.81 GSK3B (0.61) GSK3BCES2CES1SRD5A2NR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7038070-B2 Preparation of preparing substituted indanones BASELL POLYOLEFINE GMBH (DE) 2006-05-02 US disclosed
US-6963017-B2 Preparation of preparing substituted indanones BASELL POLYOLEFINE GMBH (DE) 2005-11-08 US disclosed
EP-0968158-B1 METHOD OF PREPARING SUBSTITUTED INDANONES, THE SUBSTITUTED INDANONES AND METALLOCENES PREPARED THEREFROM BASELL POLYOLEFINE GMBH (DE) 2005-08-10 EP disclosed
US-20050033076-A1 Preparation of preparing substituted indanones EQUISTAR CHEMICALS, LP 2005-02-10 US disclosed
US-20030009046-A1 Preparation of preparing substituted indanones EQUISTAR CHEMICALS, LP 2003-01-09 US disclosed
EP-0968158-A1 METHOD OF PREPARING SUBSTITUTED INDANONES, THE SUBSTITUTED INDANONES AND METALLOCENES PREPARED THEREFROM Basell Polyolefine GmbH (DE) 2000-01-05 EP disclosed
WO-1998040331-A1 PREPARATION OF PREPARING SUBSTITUTED INDANONES TARGOR GMBH (DE) 1998-09-17 WO disclosed
EP-0158448-B1 AZOLYL PROPANOLS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-08-29 EP disclosed
US-4833159-A FUNGICIDES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1989-05-23 US disclosed
US-4689337-A 1,2,4-TRIAZOLYL AND PYRAZOLYL GROUPS; FUNGICIDES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1987-08-25 US disclosed
EP-0158448-A2 Azolyl propanols IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1985-10-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050033076-A1 Preparation of preparing substituted indanones CYP1A2, CYP2J2, IDH3A GSK3B 1969/4885CES2 1925/4885CES1 3217/4885
US-20030009046-A1 Preparation of preparing substituted indanones CYP1A2, CYP1B1, CYP1A1 GSK3B 2285/4885CES2 1961/4885CES1 2736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.